drug_type
RELEVANT_DRUG
intervention_type
Cellular therapy (CAR T cells)
drug_description
Engineered autologous T cells expressing a chimeric antigen receptor targeting GPRC5D on malignant plasma cells.
nci_thesaurus_definition
NCI thesaurus definition not available.
drug_mesh_term
Chimeric Antigen Receptor T-Cell Therapy
drug_category
CAR T
drug_class
Cellular Therapy
drug_delivery_route
Intravenous
drug_mechanism_of_action
Autologous T cells are genetically engineered to express a chimeric antigen receptor that binds GPRC5D on malignant plasma cells. Antigen engagement triggers CAR signaling, activating the T cells to proliferate, secrete cytokines, and kill GPRC5D-positive myeloma cells via perforin/granzyme-mediated cytotoxicity.
drug_name
GPRC5D-directed CAR T cells
nct_id_drug_ref
NCT06205823